Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telitacicept in Early Stage SLE
NCT05899907Phase 4Unknown
- Sponsor
- Peking Union Medical College Hospital
- Start
- Sep 2022
- Primary completion
- Mar 2025
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of telitacicept in systemic lupus erythematosus (SLE) (2 arms), sponsored by Peking Union Medical College Hospital. Primary endpoint: Lupus Low Disease Activity State at 24 weeks. Status: unknown.
02
Drugs
telitacicept
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT05899907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05899907.